Barry E M, Gomez-Duarte O, Chatfield S, Rappuoli R, Pizza M, Losonsky G, Galen J, Levine M M
Center for Vaccine Development, University of Maryland School of Medicine, Baltimore 21201, USA.
Infect Immun. 1996 Oct;64(10):4172-81. doi: 10.1128/iai.64.10.4172-4181.1996.
Salmonella typhi vaccine strain CVD 908 can deliver heterologous antigens to the host immune system following mucosal immunization. Stable expression of foreign proteins in Salmonella cells often requires antigen-specific engineering strategies. Fusion of antigens to stabilizing proteins has proven to be a successful strategy for rescuing otherwise unstable proteins. We designed plasmids to allow the fusion of antigens to the amino terminus or carboxyl terminus of fragment C of tetanus toxin, separated by a 4-amino-acid hinge region. Towards the ultimate goal of developing a live oral diphtheria-pertussis-tetanus vaccine, we used these plasmids to stably express the S1 subunit of pertussis toxin in CVD 908. Driven by the anaerobically inducible nirB promoter, the S1 subunit alone was expressed poorly in Salmonella cytoplasm. In contrast, hybrid proteins with S1 fused to either the amino or carboxyl terminus of fragment C were expressed at a high level in CVD 908 and were recognized in Western blot (immunoblot) analysis by monoclonal antibodies directed to S1 and to fragment C. Mice were immunized by the oral or intranasal routes with CVD 908 derivatives harboring these recombinant plasmids. All fusion proteins elicited serum antibody responses to fragment C following intranasal immunization, whereas oral inoculation did not. The configuration of antigens constituting the fusion was critical; S1 fused to the amino terminus of fragment C was less effective than S1 fused to the carboxyl terminus in generating anti-fragment C antibodies. CVD 908 expressing truncated S1 fused to the carboxyl terminus of fragment C elicited neutralizing serum pertussis antitoxin following intranasal immunization of mice.
伤寒沙门氏菌疫苗株CVD 908在黏膜免疫后可将异源抗原递呈给宿主免疫系统。在沙门氏菌细胞中稳定表达外源蛋白通常需要抗原特异性工程策略。将抗原与稳定蛋白融合已被证明是拯救原本不稳定蛋白的成功策略。我们设计了质粒,使抗原能够与破伤风毒素C片段的氨基末端或羧基末端融合,中间由一个4氨基酸的铰链区隔开。为了实现开发一种口服白喉-百日咳-破伤风活疫苗的最终目标,我们使用这些质粒在CVD 908中稳定表达百日咳毒素的S1亚基。在厌氧诱导的nirB启动子驱动下,单独的S1亚基在沙门氏菌细胞质中表达不佳。相比之下,S1与C片段的氨基末端或羧基末端融合的杂合蛋白在CVD 908中高水平表达,并在蛋白质免疫印迹(免疫印迹)分析中被针对S1和C片段的单克隆抗体识别。用携带这些重组质粒的CVD 908衍生物通过口服或鼻内途径免疫小鼠。所有融合蛋白在鼻内免疫后均引发了针对C片段的血清抗体反应,而口服接种则没有。构成融合体的抗原构型至关重要;与C片段羧基末端融合的S1在产生抗C片段抗体方面比与氨基末端融合的S1效果更差。在小鼠鼻内免疫后,表达与C片段羧基末端融合的截短S1的CVD 908引发了中和性血清百日咳抗毒素。